Heterogeneity of molecular markers in chronic myelomonocytic leukemia: A disease associated with several gene alterations

Cellular and Molecular Life Sciences

Volumn 69, Issue 17, 2012, Pages 2853-2861

  Bastie, Jean Noël ^a,b   Aucagne, Romain ^a,c   Droin, Nathalie ^d   Solary, Eric ^d   Delva, Laurent ^a  

^a UNIVERSITÉ DE BOURGOGNE   (France)

^b DIJON UNIVERSITY HOSPITAL   (France)

^c INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

^d INSERM   (France)

Author keywords

Biomarkers; Chronic myelomonocytic leukemia; Heterogeneity; Mouse models; Somatic mutations

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; CBL PROTEIN; CD135 ANTIGEN; CYTARABINE; DNA METHYLTRANSFERASE 3A; ETOPOSIDE; HYDROXYUREA; ISOCITRATE DEHYDROGENASE; JANUS KINASE 2; MOLECULAR MARKER; NOTCH RECEPTOR; NUCLEOPHOSMIN; THALIDOMIDE; TRANSCRIPTION FACTOR EZH2; TRANSCRIPTION FACTOR RUNX1;

ACUTE GRANULOCYTIC LEUKEMIA; AGE; ALLOGENEIC STEM CELL TRANSPLANTATION; ANEMIA; CANCER PROGNOSIS; CASITAS B LINEAGE LYMPHOMA GENE; CHROMOSOME ABERRATION; CHRONIC MYELOMONOCYTIC LEUKEMIA; COMORBIDITY; DNA (CYTOSINE 5 ) METHYLTRANSFERASE 3 GENE; DNA METHYLATION; DOWN REGULATION; ENHANCER OF ZESTE 2 GENE; EPIGENETICS; FATIGUE; FEVER; FMS LIKE TYROSINE KINASE 3 GENE; GENE; GENE DELETION; GENE MUTATION; GENETIC HETEROGENEITY; GENETIC TRANSCRIPTION; HUMAN; ISOCITRATE DEHYDROGENASE GENE; JANUS KINASE 2 GENE; LEUKOCYTE COUNT; LEUKOCYTOSIS; MALIGNANT TRANSFORMATION; MONOCYTOSIS; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; NIGHT SWEAT; NOTCH GENE; NUCLEOPHOSMIN 1 GENE; ONCOGENE RAS; OVERALL SURVIVAL; REVIEW; RUNT RELATED TRANSCRIPTION FACTOR 1 GENE; SPLENOMEGALY; SPLICING DEFECT; SURVIVAL TIME; TEN ELEVEN TRANSLOCATION 2 GENE; TRANSCRIPTION INTERMEDIARY FACTOR 1 GAMMA GENE; UBIQUITOUSLY TRANSCRIBED TETRATRICOPEPTIDE REPEAT GENE; UNIPARENTAL DISOMY; WEIGHT REDUCTION;

GENETIC VARIATION; HUMANS; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; NEOPLASM PROTEINS; ONCOGENE PROTEINS, FUSION; TUMOR MARKERS, BIOLOGICAL;

EID: 84864973755     PISSN: 1420682X     EISSN: 14209071     Source Type: Journal    
DOI: 10.1007/s00018-012-0956-y     Document Type: Review

References (81)

1. F Onida HM Kantarjian TL Smith G Ball MJ Keating EH Estey AB Glassman M Albitar MI Kwari M Beran 2002 Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients Blood 99 840 849 11806985 1:CAS:528:DC%2BD38XhtValsLk%3D
2. E Such J Cervera D Costa F Sole T Vallespi E Luno R Collado MJ Calasanz JM Hernandez-Rivas JC Cigudosa B Nomdedeu M Mallo F Carbonell J Bueno MT Ardanaz F Ramos M Tormo R Sancho-Tello C del Canizo V Gomez V Marco B Xicoy S Bonanad C Pedro T Bernal GF Sanz 2011 Cytogenetic risk stratification in chronic myelomonocytic leukemia Haematologica 96 375 383 21109693
3. JE Spence RG Perciaccante GM Greig HF Willard DH Ledbetter JF Hejtmancik MS Pollack WE O'Brien AL Beaudet 1988 Uniparental disomy as a mechanism for human genetic disease Am J Hum Genet 42 217 226 2893543 1:STN:280: DyaL1c7jtFSguw%3D%3D
4. AJ Dunbar LP Gondek CL O'Keefe H Makishima MS Rataul H Szpurka MA Sekeres XF Wang MA McDevitt JP Maciejewski 2008 250 K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies Cancer Res 68 10349 10357 19074904 1:CAS:528:DC%2BD1cXhsV2itL%2FE
5. AM Jankowska H Szpurka RV Tiu H Makishima M Afable J Huh CL O'Keefe R Ganetzky MA McDevitt JP Maciejewski 2009 Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms Blood 113 6403 6410 19372255 1:CAS:528:DC%2BD1MXnvFGns7Y%3D
6. A Kohlmann V Grossmann HU Klein S Schindela T Weiss B Kazak F Dicker S Schnittger M Dugas W Kern C Haferlach T Haferlach 2010 Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1 J Clin Oncol 28 3858 3865 20644105 1:CAS:528:DC%2BC3cXhtFyhsrbL
7. O Kosmider V Gelsi-Boyer M Ciudad C Racoeur V Jooste N Vey B Quesnel P Fenaux JN Bastie O Beyne-Rauzy A Stamatoulas F Dreyfus N Ifrah S de Botton W Vainchenker OA Bernard D Birnbaum M Fontenay E Solary 2009 TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia Haematologica 94 1676 1681 19797729 1:CAS:528:DC%2BC3cXhsVSitL0%3D
8. V Gelsi-Boyer V Trouplin J Adelaide N Aceto V Remy S Pinson C Houdayer C Arnoulet D Sainty M Bentires-Alj S Olschwang N Vey MJ Mozziconacci D Birnbaum M Chaffanet 2008 Genome profiling of chronic myelomonocytic leukemia: frequent alterations of RAS and RUNX1 genes BMC Cancer 8 299 18925961
9. MC Kuo DC Liang CF Huang YS Shih JH Wu TL Lin LY Shih 2009 RUNX1 mutations are frequent in chronic myelomonocytic leukemia and mutations at the C-terminal region might predict acute myeloid leukemia transformation Leukemia 23 1426 1431 19282830 1:CAS:528:DC%2BD1MXpvF2kurg%3D
10. V Gelsi-Boyer V Trouplin J Adelaide J Bonansea N Cervera N Carbuccia A Lagarde T Prebet M Nezri D Sainty S Olschwang L Xerri M Chaffanet MJ Mozziconacci N Vey D Birnbaum 2009 Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia Br J Haematol 145 788 800 19388938 1:CAS:528:DC%2BD1MXosVartbw%3D
11. K Yoshida M Sanada Y Shiraishi D Nowak Y Nagata R Yamamoto Y Sato A Sato-Otsubo A Kon M Nagasaki G Chalkidis Y Suzuki M Shiosaka R Kawahata T Yamaguchi M Otsu N Obara M Sakata-Yanagimoto K Ishiyama H Mori F Nolte WK Hofmann S Miyawaki S Sugano C Haferlach HP Koeffler LY Shih T Haferlach S Chiba H Nakauchi S Miyano S Ogawa 2011 Frequent pathway mutations of splicing machinery in myelodysplasia Nature 478 64 69 21909114 1:CAS:528: DC%2BC3MXhtFGnur3M
12. JW Tyner H Erickson MW Deininger SG Willis CA Eide RL Levine MC Heinrich N Gattermann DG Gilliland BJ Druker MM Loriaux 2009 High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients Blood 113 1749 1755 19075190 1:CAS:528:DC%2BD1MXisV2iu7k%3D
13. J Jelinek Y Oki V Gharibyan C Bueso-Ramos JT Prchal S Verstovsek M Beran E Estey HM Kantarjian JP Issa 2005 JAK2 mutation 1849G > T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia Blood 106 3370 3373 16037387 1:CAS:528: DC%2BD2MXht1ehsb7L
14. BH Lee Z Tothova RL Levine K Anderson N Buza-Vidas DE Cullen EP McDowell J Adelsperger S Frohling BJ Huntly M Beran SE Jacobsen DG Gilliland 2007 FLT3 mutations confer enhanced proliferation and survival properties to multipotent progenitors in a murine model of chronic myelomonocytic leukemia Cancer Cell 12 367 380 17936561 1:CAS:528:DC%2BD2sXht1ais7zJ
15. A Klinakis C Lobry O Abdel-Wahab P Oh H Haeno S Buonamici I van De Walle S Cathelin T Trimarchi E Araldi C Liu S Ibrahim M Beran J Zavadil A Efstratiadis T Taghon F Michor RL Levine I Aifantis 2011 A novel tumour-suppressor function for the notch pathway in myeloid leukaemia Nature 473 230 233 21562564 1:CAS:528:DC%2BC3MXlvFGmtb0%3D
16. F Viguie A Aboura D Bouscary S Ramond A Delmer G Tachdjian JP Marie N Casadevall 2005 Common 4q24 deletion in four cases of hematopoietic malignancy: early stem cell involvement? Leukemia 19 1411 1415 15920487 1:CAS:528: DC%2BD2MXmtlSjsrY%3D
17. O Abdel-Wahab A Mullally C Hedvat G Garcia-Manero J Patel M Wadleigh S Malinge J Yao O Kilpivaara R Bhat K Huberman S Thomas I Dolgalev A Heguy E Paietta MM Le Beau M Beran MS Tallman BL Ebert HM Kantarjian RM Stone DG Gilliland JD Crispino RL Levine 2009 Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies Blood 114 144 147 19420352 1:CAS:528:DC%2BD1MXhtVOkurvO
18. U Bacher S Weissmann A Kohlmann S Schindela T Alpermann S Schnittger W Kern T Haferlach C Haferlach 2012 TET2 deletions are a recurrent but rare phenomenon in myeloid malignancies and are frequently accompanied by TET2 mutations on the remaining allele Br J Haematol 156 67 75 22017486
19. T Ernst AJ Chase J Score CE Hidalgo-Curtis C Bryant AV Jones K Waghorn K Zoi FM Ross A Reiter A Hochhaus HG Drexler A Duncombe F Cervantes D Oscier J Boultwood FH Grand NC Cross 2010 Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders Nat Genet 42 722 726 20601953 1:CAS:528:DC%2BC3cXotlWktLs%3D
20. V Grossmann A Kohlmann C Eder C Haferlach W Kern NC Cross T Haferlach S Schnittger 2011 Molecular profiling of chronic myelomonocytic leukemia reveals diverse mutations in >80 % of patients with TET2 and EZH2 being of high prognostic relevance Leukemia 25 877 879 21339759 1:CAS:528:DC%2BC3MXlvFCks70%3D
21. A Tefferi KH Lim R Levine 2009 Mutation in TET2 in myeloid cancers N Engl J Med 361 1117 19741235 1:CAS:528:DC%2BD1MXhtFartbnI author reply 1117-1118
22. T Braun R Itzykson A Renneville B de Renzis F Dreyfus K Laribi K Bouabdallah N Vey A Toma C Recher B Royer B Joly A Vekhoff I Lafon L Sanhes G Meurice C Orear C Preudhomme C Gardin L Ades M Fontenay P Fenaux N Droin E Solary 2011 Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase two trial Blood 118 3824 3831 21828134 1:CAS:528:DC%2BC3MXhtlCgtb%2FL
23. AM Jankowska H Makishima RV Tiu H Szpurka Y Huang F Traina V Visconte Y Sugimoto C Prince C O'Keefe ED Hsi A List MA Sekeres A Rao MA McDevitt JP Maciejewski 2011 Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A Blood 118 3932 3941 21828135 1:CAS:528:DC%2BC3MXhtlCgtbzE
24. ME Figueroa O Abdel-Wahab C Lu PS Ward J Patel A Shih Y Li N Bhagwat A Vasanthakumar HF Fernandez MS Tallman Z Sun K Wolniak JK Peeters W Liu SE Choe VR Fantin E Paietta B Lowenberg JD Licht LA Godley R Delwel PJ Valk CB Thompson RL Levine A Melnick 2010 Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation Cancer Cell 18 553 567 21130701 1:CAS:528:DC%2BC3cXhsFGhsbvJ
25. N Carbuccia V Trouplin V Gelsi-Boyer A Murati J Rocquain J Adelaide S Olschwang L Xerri N Vey M Chaffanet D Birnbaum MJ Mozziconacci 2010 Mutual exclusion of ASXL1 and NPM1 mutations in a series of acute myeloid leukemias Leukemia 24 469 473 19865112 1:STN:280:DC%2BC3c%2Fps1SjtA%3D%3D
26. V Gelsi-Boyer V Trouplin J Roquain J Adelaide N Carbuccia B Esterni P Finetti A Murati C Arnoulet H Zerazhi H Fezoui Z Tadrist M Nezri M Chaffanet MJ Mozziconacci N Vey D Birnbaum 2010 ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia Br J Haematol 151 365 375 20880116 1:CAS:528:DC%2BC3cXhs1aisL%2FM
27. K Agger PA Cloos J Christensen D Pasini S Rose J Rappsilber I Issaeva E Canaani AE Salcini K Helin 2007 UTX and JMJD3 are histone H3K27 demethylases involved in HOX gene regulation and development Nature 449 731 734 17713478 1:CAS:528:DC%2BD2sXhtFChu77P
28. G van Haaften GL Dalgliesh H Davies L Chen G Bignell C Greenman S Edkins C Hardy S O'Meara J Teague A Butler J Hinton C Latimer J Andrews S Barthorpe D Beare G Buck PJ Campbell J Cole S Forbes M Jia D Jones CY Kok C Leroy ML Lin DJ McBride M Maddison S Maquire K McLay A Menzies T Mironenko L Mulderrig L Mudie E Pleasance R Shepherd R Smith L Stebbings P Stephens G Tang PS Tarpey R Turner K Turrell J Varian S West S Widaa P Wray VP Collins K Ichimura S Law J Wong ST Yuen SY Leung G Tonon RA DePinho YT Tai KC Anderson RJ Kahnoski A Massie SK Khoo BT Teh MR Stratton PA Futreal 2009 Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer Nat Genet 41 521 523 19330029
29. E Vire C Brenner R Deplus L Blanchon M Fraga C Didelot L Morey A Van Eynde D Bernard JM Vanderwinden M Bollen M Esteller L Di Croce Y de Launoit F Fuks 2006 The polycomb group protein EZH2 directly controls DNA methylation Nature 439 871 874 16357870 1:CAS:528:DC%2BD28XhsVSkur0%3D
30. TJ Ley L Ding MJ Walter MD McLellan T Lamprecht DE Larson C Kandoth JE Payton J Baty J Welch CC Harris CF Lichti RR Townsend RS Fulton DJ Dooling DC Koboldt H Schmidt Q Zhang JR Osborne L Lin M O'Laughlin JF McMichael KD Delehaunty SD McGrath LA Fulton VJ Magrini TL Vickery J Hundal LL Cook JJ Conyers GW Swift JP Reed PA Alldredge T Wylie J Walker J Kalicki MA Watson S Heath WD Shannon N Varghese R Nagarajan P Westervelt MH Tomasson DC Link TA Graubert JF DiPersio ER Mardis RK Wilson 2010 DNMT3A mutations in acute myeloid leukemia N Engl J Med 363 2424 2433 21067377 1:CAS:528:DC%2BC3cXhsF2ltb7K
31. K Kumano M Kurokawa 2010 The role of Runx1/AML1 and Evi-1 in the regulation of hematopoietic stem cells J Cell Physiol 222 282 285 19847803 1:CAS:528:DC%2BD1MXhsFSgsrrI
32. Y Harada H Harada 2009 Molecular pathways mediating MDS/AML with focus on AML1/RUNX1 point mutations J Cell Physiol 220 16 20 19334039 1:CAS:528:DC%2BD1MXmvVGit70%3D
33. M Constantinidou G Chalevelakis T Economopoulos M Koffa T Liloglou C Anastassiou A Yalouris DA Spandidos S Raptis 1997 Codon 12 ras mutations in patients with myelodysplastic syndrome: incidence and prognostic value Ann Hematol 74 11 14 9031609 1:CAS:528:DyaK2sXps1Ohuw%3D%3D
34. EJ Feldman J Cortes DJ DeAngelo T Holyoake B Simonsson SG O'Brien J Reiffers AR Turner GJ Roboz JH Lipton F Maloisel P Colombat G Martinelli JL Nielsen S Petersdorf F Guilhot J Barker P Kirschmeier E Frank P Statkevich Y Zhu S Loechner A List 2008 On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia Leukemia 22 1707 1711 18548095 1:CAS:528:DC%2BD1cXhtVyqu7zF
35. JE Karp K Flatten EJ Feldman JM Greer DA Loegering RM Ricklis LE Morris E Ritchie BD Smith V Ironside T Talbott G Roboz SB Le XW Meng PA Schneider NT Dai AA Adjei SD Gore MJ Levis JJ Wright E Garrett-Mayer SH Kaufmann 2009 Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide Blood 113 4841 4852 19109557 1:CAS:528:DC%2BD1MXmslalsb0%3D
36. G Swaminathan AY Tsygankov 2006 The Cbl family proteins: ring leaders in regulation of cell signaling J Cell Physiol 209 21 43 16741904 1:CAS:528:DC%2BD28Xpt1arsrw%3D
37. SR Bandi C Brandts M Rensinghoff R Grundler L Tickenbrock G Kohler J Duyster WE Berdel C Muller-Tidow H Serve B Sargin 2009 E3 ligase-defective Cbl mutants lead to a generalized mastocytosis and myeloproliferative disease Blood 114 4197 4208 19734451 1:CAS:528:DC%2BD1MXhsVGku7jO
38. B Sargin C Choudhary N Crosetto MH Schmidt R Grundler M Rensinghoff C Thiessen L Tickenbrock J Schwable C Brandts B August S Koschmieder SR Bandi J Duyster WE Berdel C Muller-Tidow I Dikic H Serve 2007 Flt3-dependent transformation by inactivating c-Cbl mutations in AML Blood 110 1004 1012 17446348 1:CAS:528:DC%2BD2sXos1Cqtr8%3D
39. M Sanada T Suzuki LY Shih M Otsu M Kato S Yamazaki A Tamura H Honda M Sakata-Yanagimoto K Kumano H Oda T Yamagata J Takita N Gotoh K Nakazaki N Kawamata M Onodera M Nobuyoshi Y Hayashi H Harada M Kurokawa S Chiba H Mori K Ozawa M Omine H Hirai H Nakauchi HP Koeffler S Ogawa 2009 Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms Nature 460 904 908 19620960 1:CAS:528:DC%2BD1MXoslentrg%3D
40. FH Grand CE Hidalgo-Curtis T Ernst K Zoi C Zoi C McGuire S Kreil A Jones J Score G Metzgeroth D Oscier A Hall C Brandts H Serve A Reiter AJ Chase NC Cross 2009 Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms Blood 113 6182 6192 19387008 1:CAS:528:DC%2BD1MXnslSmu7Y%3D
41. ML Loh DS Sakai C Flotho M Kang M Fliegauf S Archambeault CG Mullighan L Chen E Bergstraesser CE Bueso-Ramos PD Emanuel H Hasle JP Issa MM van den Heuvel-Eibrink F Locatelli J Stary M Trebo M Wlodarski M Zecca KM Shannon CM Niemeyer 2009 Mutations in CBL occur frequently in juvenile myelomonocytic leukemia Blood 114 1859 1863 19571318 1:CAS:528:DC%2BD1MXhtFWgsbfP
42. H Makishima H Cazzolli H Szpurka A Dunbar R Tiu J Huh H Muramatsu C O'Keefe E Hsi RL Paquette S Kojima AF List MA Sekeres MA McDevitt JP Maciejewski 2009 Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies J Clin Oncol 27 6109 6116 19901108 1:CAS:528:DC%2BC3cXht1agsLk%3D
43. H Muramatsu H Makishima AM Jankowska H Cazzolli C O'Keefe N Yoshida Y Xu N Nishio A Hama H Yagasaki Y Takahashi K Kato A Manabe S Kojima JP Maciejewski 2010 Mutations of an E3 ubiquitin ligase c-Cbl but not TET2 mutations are pathogenic in juvenile myelomonocytic leukemia Blood 115 1969 1975 20008299 1:CAS:528:DC%2BC3cXhtFensbbI
44. W Vainchenker F Delhommeau SN Constantinescu OA Bernard 2011 New mutations and pathogenesis of myeloproliferative neoplasms Blood 118 1723 1735 21653328 1:CAS:528:DC%2BC3MXhtFeqsLfP
45. MA Dawson AJ Bannister B Gottgens SD Foster T Bartke AR Green T Kouzarides 2009 JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin Nature 461 819 822 19783980 1:CAS:528:DC%2BD1MXhtFygsLjM
46. I Plo W Vainchenker 2009 Molecular and genetic bases of myeloproliferative disorders: questions and perspectives Clin Lymphoma Myeloma 9 Suppl 3 S329 S339 19778861 1:CAS:528:DC%2BD1MXhtlantLfN
47. FM Abu-Duhier AC Goodeve GA Wilson MA Gari IR Peake DC Rees EA Vandenberghe PR Winship JT Reilly 2000 FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group Br J Haematol 111 190 195 11091200 1:CAS:528:DC%2BD3cXosFSnsr4%3D
48. MS Davids DP Steensma 2010 The molecular pathogenesis of myelodysplastic syndromes Cancer Biol Ther 10 309 319 20592488 1:CAS:528:DC%2BC3cXhsFSrs7jJ
49. B De Strooper 2005 Nicastrin: gatekeeper of the gamma-secretase complex Cell 122 318 320 16096051
50. I Aifantis E Raetz S Buonamici 2008 Molecular pathogenesis of T-cell leukaemia and lymphoma Nat Rev Immunol 8 380 390 18421304 1:CAS:528: DC%2BD1cXltFejsbk%3D
51. B Falini MP Martelli N Bolli P Sportoletti A Liso E Tiacci T Haferlach 2011 Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity? Blood 117 1109 1120 21030560 1:CAS:528:DC%2BC3MXhvFGlu7Y%3D
52. JS Caudill AJ Sternberg CY Li A Tefferi TL Lasho DP Steensma 2006 C-terminal nucleophosmin mutations are uncommon in chronic myeloid disorders Br J Haematol 133 638 641 16704439 1:CAS:528:DC%2BD28XmslCrsL4%3D
53. R Xiao Y Sun JH Ding S Lin DW Rose MG Rosenfeld XD Fu X Li 2007 Splicing regulator SC35 is essential for genomic stability and cell proliferation during mammalian organogenesis Mol Cell Biol 27 5393 5402 17526736 1:CAS:528: DC%2BD2sXoslKru70%3D
54. R Beckstead JA Ortiz C Sanchez SN Prokopenko P Chambon R Losson HJ Bellen 2001 Bonus, a Drosophila homolog of TIF1 proteins, interacts with nuclear receptors and can inhibit betaFTZ-F1-dependent transcription Mol Cell 7 753 765 11336699 1:CAS:528:DC%2BD3MXjsVentL4%3D
55. JR Friedman WJ Fredericks DE Jensen DW Speicher XP Huang EG Neilson FJ Rauscher 3rd 1996 KAP-1, a novel corepressor for the highly conserved KRAB repression domain Genes Dev 10 2067 2078 8769649 1:CAS:528:DyaK28XlsVaqt7k%3D
56. K Khetchoumian M Teletin M Mark T Lerouge M Cervino M Oulad-Abdelghani P Chambon R Losson 2004 TIF1delta, a novel HP1-interacting member of the transcriptional intermediary factor 1 (TIF1) family expressed by elongating spermatids J Biol Chem 279 48329 48341 15322135 1:CAS:528:DC%2BD2cXptl2nurg%3D
57. B Le Douarin C Zechel JM Garnier Y Lutz L Tora P Pierrat D Heery H Gronemeyer P Chambon R Losson 1995 The N-terminal part of TIF1, a putative mediator of the ligand-dependent activation function (AF-2) of nuclear receptors, is fused to B-raf in the oncogenic protein T18 EMBO J 14 2020 2033 7744009
58. P Moosmann O Georgiev B Le Douarin JP Bourquin W Schaffner 1996 Transcriptional repression by RING finger protein TIF1 beta that interacts with the KRAB repressor domain of KOX1 Nucleic Acids Res 24 4859 4867 9016654 1:CAS:528:DyaK2sXjvFykug%3D%3D
59. L Venturini J You M Stadler R Galien V Lallemand MH Koken MG Mattei A Ganser P Chambon R Losson H de The 1999 TIF1gamma, a novel member of the transcriptional intermediary factor 1 family Oncogene 18 1209 1217 10022127 1:CAS:528:DyaK1MXhsVyrsbg%3D
60. S Zhong L Delva C Rachez C Cenciarelli D Gandini H Zhang S Kalantry LP Freedman PP Pandolfi 1999 A RA-dependent, tumour-growth suppressive transcription complex is the target of the PML-RARalpha and T18 oncoproteins Nat Genet 23 287 295 10610177 1:CAS:528:DyaK1MXnt1GnsrY%3D
61. K Khetchoumian M Teletin J Tisserand M Mark B Herquel M Ignat J Zucman-Rossi F Cammas T Lerouge C Thibault D Metzger P Chambon R Losson 2007 Loss of Trim24 (Tif1alpha) gene function confers oncogenic activity to retinoic acid receptor alpha Nat Genet 39 1500 1506 18026104 1:CAS:528:DC%2BD2sXhtlKmtLrJ
62. C Underhill MS Qutob SP Yee J Torchia 2000 A novel nuclear receptor corepressor complex, N-CoR, contains components of the mammalian SWI/SNF complex and the corepressor KAP-1 J Biol Chem 275 40463 40470 11013263 1:CAS:528:DC%2BD3MXhsFertQ%3D%3D
63. M Abrink JA Ortiz C Mark C Sanchez C Looman L Hellman P Chambon R Losson 2001 Conserved interaction between distinct Kruppel-associated box domains and the transcriptional intermediary factor 1 beta Proc Natl Acad Sci (USA) 98 1422 1426 1:CAS:528:DC%2BD3MXhsVWjt78%3D
64. F Cammas M Mark P Dolle A Dierich P Chambon R Losson 2000 Mice lacking the transcriptional corepressor TIF1beta are defective in early postimplantation development Development 127 2955 2963 10851139 1:CAS:528:DC%2BD3cXlt1GmtL8%3D
65. DG Ransom N Bahary K Niss D Traver C Burns NS Trede N Paffett-Lugassy WJ Saganic CA Lim C Hersey Y Zhou BA Barut S Lin PD Kingsley J Palis SH Orkin LI Zon 2004 The zebrafish moonshine gene encodes transcriptional intermediary factor 1gamma, an essential regulator of hematopoiesis PLoS Biol 2 E237 15314655
66. X Bai J Kim Z Yang MJ Jurynec TE Akie J Lee J LeBlanc A Sessa H Jiang A DiBiase Y Zhou DJ Grunwald S Lin AB Cantor SH Orkin LI Zon 2010 TIF1gamma controls erythroid cell fate by regulating transcription elongation Cell 142 133 143 20603019 1:CAS:528:DC%2BC3cXpt1CjtLg%3D
67. R Aucagne N Droin J Paggetti B Lagrange A Largeot A Hammann A Bataille L Martin KP Yan P Fenaux R Losson E Solary JN Bastie L Delva 2011 Transcription intermediary factor 1gamma is a tumor suppressor in mouse and human chronic myelomonocytic leukemia J Clin Invest 121 2361 2370 21537084 1:CAS:528:DC%2BC3MXnsVaitr0%3D
68. S Kusy N Gault F Ferri D Lewandowski V Barroca A Jaracz-Ros R Losson PH Romeo 2011 Adult hematopoiesis is regulated by TIF1gamma, a repressor of TAL1 and PU.1 transcriptional activity Cell Stem Cell 8 412 425 21474105 1:CAS:528:DC%2BC3MXksFGns70%3D
69. H Kantarjian Y Oki G Garcia-Manero X Huang S O'Brien J Cortes S Faderl C Bueso-Ramos F Ravandi Z Estrov A Ferrajoli W Wierda J Shan J Davis F Giles HI Saba JP Issa 2007 Results of a randomized study of three schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia Blood 109 52 57 16882708 1:CAS:528:DC%2BD2sXivVyrt7c%3D
70. C Parikh R Subrahmanyam R Ren 2006 Oncogenic NRAS rapidly and efficiently induces CMML- and AML-like diseases in mice Blood 108 2349 2357 16763213 1:CAS:528:DC%2BD28XhtVCgur%2FL
71. B Cuiffo R Ren 2010 Palmitoylation of oncogenic NRAS is essential for leukemogenesis Blood 115 3598 3605 20200357 1:CAS:528:DC%2BC3cXmtFylurc%3D
72. J Wang Y Liu Z Li J Du MJ Ryu PR Taylor MD Fleming KH Young H Pitot J Zhang 2010 Endogenous oncogenic Nras mutation promotes aberrant GM-CSF signaling in granulocytic/monocytic precursors in a murine model of chronic myelomonocytic leukemia Blood 116 5991 6002 20921338 1:CAS:528: DC%2BC3MXktFyhsA%3D%3D
73. E Wattel A Guerci B Hecquet T Economopoulos A Copplestone B Mahe ME Couteaux L Resegotti V Voglova C Foussard B Pegourie JL Michaux E Deconinck AM Stoppa G Mufti D Oscier P Fenaux 1996 A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia. Groupe Francais des myelodysplasies and European CMML Group Blood 88 2480 2487 8839839 1:CAS:528:DyaK28XmtFSjtbc%3D
74. H Kantarjian JP Issa CS Rosenfeld JM Bennett M Albitar J DiPersio V Klimek J Slack C de Castro F Ravandi R Helmer 3rd L Shen SD Nimer R Leavitt A Raza H Saba 2006 Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study Cancer 106 1794 1803 16532500 1:CAS:528:DC%2BD28XksFCrsrk%3D
75. LR Silverman EP Demakos BL Peterson AB Kornblith JC Holland R Odchimar-Reissig RM Stone D Nelson BL Powell CM DeCastro J Ellerton RA Larson CA Schiffer JF Holland 2002 Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B J Clin Oncol 20 2429 2440 12011120 1:CAS:528:DC%2BD38XksFakur8%3D
76. R Costa H Abdulhaq B Haq RK Shadduck J Latsko M Zenati FD Atem JM Rossetti EA Sahovic J Lister 2011 Activity of azacitidine in chronic myelomonocytic leukemia Cancer 117 2690 2696 21656746 1:CAS:528: DC%2BC3MXnt1Krtrc%3D
77. P Fenaux GJ Mufti E Hellstrom-Lindberg V Santini C Finelli A Giagounidis R Schoch N Gattermann G Sanz A List SD Gore JF Seymour JM Bennett J Byrd J Backstrom L Zimmerman D McKenzie C Beach LR Silverman 2009 Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study Lancet Oncol 10 223 232 19230772 1:CAS:528:DC%2BD1MXisFWjsbc%3D
78. PW Wijermans B Ruter MR Baer JL Slack HI Saba M Lubbert 2008 Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML) Leuk Res 32 587 591 17881052 1:CAS:528:DC%2BD1cXitlOhsLY%3D
79. SD Gore S Baylin E Sugar H Carraway CB Miller M Carducci M Grever O Galm T Dauses JE Karp MA Rudek M Zhao BD Smith J Manning A Jiemjit G Dover A Mays J Zwiebel A Murgo LJ Weng JG Herman 2006 Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms Cancer Res 66 6361 6369 16778214 1:CAS:528:DC%2BD28XlvVSkurc%3D
80. A Raza M Mehdi M Mumtaz F Ali S Lascher N Galili 2008 Combination of 5-azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia Cancer 113 1596 1604 18720364 1:CAS:528: DC%2BD1cXht1Ggu7bP
81. I Moller S Blum N Gattermann R Haas K Habersang U Germing A Kuendgen 2009 Repeated responses of an elderly patient with high-risk myelodysplastic syndrome to sequential therapy with tipifarnib, 5-azacitidine, and decitabine Ann Hematol 88 1141 1144 19290525